AGT 187
Alternative Names: AGT-187Latest Information Update: 28 Oct 2022
Price :
$50 *
At a glance
- Originator ArmaGen Technologies
- Class Enzymes; Immunoglobulin fusion proteins; Monoclonal antibodies
- Mechanism of Action Acetylglucosaminidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mucopolysaccharidosis III
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-III in USA (IV, Infusion)
- 21 Oct 2020 Preclinical development is ongoing for Mucopolysaccharidosis-III in USA (ArmaGen Technologies pipeline, October 2020)